Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

NCT06777368 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).

Conditions Studied

Interventions

  • DEVICE Medtronic TAV
  • DEVICE Edwards TAV

Study Locations (20)

California

  • Kaiser Permanente Los Angeles Medical Center — Los Angeles
  • Sutter Heatlh — Sacramento
  • Kaiser Permanente Northern California — Sacramento
  • Stanford Hospital & Clinics — Stanford
  • Los Robles Regional Medical Center — Thousand Oaks

Florida

  • Morton Plant Hospital — Clearwater
  • HealthPark Medical Center, Lee Memorial Health — Fort Myers
  • Orlando Health/Orlando Regional Medical Center — Orlando
  • Tampa General/USF — Tampa

Arizona

  • Abrazo Arizona Heart Hospital — Phoenix
  • Tucson Medical Center — Tucson

Connecticut

  • Hartford Hospital — Hartford
  • Yale New Haven Hospital — New Haven

Indiana

  • Parkview Health — Fort Wayne
  • Saint Vincent Heart Center of Indiana — Indianapolis

Iowa

  • MercyOne Iowa Heart Center — Des Moines
  • University of Iowa Hospitals and Clinics — Iowa City

Alabama

  • University of Alabama at Birmingham — Birmingham

Colorado

  • Medical Center of the Rockies — Loveland

Trial Details

FieldValue
Enrollment Target 225 participants
Start Date 2025-02-06
Est. Completion 2033-07

Sponsor

Medtronic Cardiovascular

49 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06777368

The ClinicalTrials.gov registry entry for NCT06777368 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 49 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Aortic Stenosis appearing as the primary indexed condition, and to 2 interventions — of which Medtronic TAV is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06777368 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06777368 about?

NCT06777368 is a clinical study titled "REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE". The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).

What is the current status of trial NCT06777368?

This trial is currently recruiting. The enrollment target is 225 participants. The study started on 2025-02-06. Estimated completion is 2033-07.

What conditions does trial NCT06777368 study?

This clinical trial studies the following conditions: Aortic Stenosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06777368?

The interventions under investigation include: Medtronic TAV (DEVICE), Edwards TAV (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06777368?

This trial is sponsored by Medtronic Cardiovascular, which has 49 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06777368 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial